| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780069 | Gynecologic Oncology | 2018 | 4 Pages |
Abstract
- Expensive novel therapeutics and underinsurance complicate the delivery of cancer care in the United States.
- “Financial toxicity” of treatment can lead to negative downstream effects (i.e., bankruptcy, non-adherence to treatment).
- Universal financial toxicity screening of cancer patients before, during, and after treatment should be standard of care.
- Identification of high-risk patients with triage to financial resources and counseling can improve cancer care delivery.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Margaret I. Liang, Warner K. Huh,